Advanced

Health-related quality of life after chemotherapy cycle in breast cancer in Iran

Bastani, Peivand and Ahmad Kiadaliri, Aliasghar LU (2011) In Medical Oncology 28(S1). p.70-74
Abstract (Swedish)
Abstract in Undetermined

The aim of this study was to compare the differences between the level of whole quality of life and its subscales after receiving two common treatment of breast cancer in women with early stage of breast cancer. A double-blinded cohort study was done in 100 breast cancer patients with node positive that used fluorouracil, doxorubicin, cyclophosphamide (FAC) and docetaxel, doxorubicin and cyclophosphamide (TAC) regimen as adjuvant therapy. Patients were followed for 4 months since the end of chemotherapy. Health-related quality of life was assessed using questionnaire (QLQ-C30) from European Organization for Research and Treatment of Cancer (EORTC). Independent t-test analysis was used at the... (More)
Abstract in Undetermined

The aim of this study was to compare the differences between the level of whole quality of life and its subscales after receiving two common treatment of breast cancer in women with early stage of breast cancer. A double-blinded cohort study was done in 100 breast cancer patients with node positive that used fluorouracil, doxorubicin, cyclophosphamide (FAC) and docetaxel, doxorubicin and cyclophosphamide (TAC) regimen as adjuvant therapy. Patients were followed for 4 months since the end of chemotherapy. Health-related quality of life was assessed using questionnaire (QLQ-C30) from European Organization for Research and Treatment of Cancer (EORTC). Independent t-test analysis was used at the significant level of 0.05 for analyzing the results. The mean of age was 48.49 +/- 10.63 in these patients. QoL scores were 64 and 68 in TAC and FAC groups, respectively (P < 0.001). After 4 months, patients in TAC and FAC groups experienced 11.45 and 7.14 units of improvement in QoL scores, respectively (P = 0.02). Although, TAC had a more negative impact on QoL during chemotherapy, it created a higher improvement than FAC during 4 months since the end of treatment. These effects on quality of life should be considered in making decision for providing and financing cancer treatments in Iran. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Quality of life, Breast cancer, FAC, TAC, Iran
in
Medical Oncology
volume
28
issue
S1
pages
70 - 74
publisher
Humana Press
external identifiers
  • wos:000301047200011
  • scopus:84655175023
ISSN
1559-131X
DOI
10.1007/s12032-010-9714-x
language
English
LU publication?
yes
id
17aaf217-1c81-451a-ba2e-c2bc5a62a52b (old id 1982699)
date added to LUP
2012-06-27 14:54:12
date last changed
2017-01-01 05:21:38
@article{17aaf217-1c81-451a-ba2e-c2bc5a62a52b,
  abstract     = {<b>Abstract in Undetermined</b><br/><br>
The aim of this study was to compare the differences between the level of whole quality of life and its subscales after receiving two common treatment of breast cancer in women with early stage of breast cancer. A double-blinded cohort study was done in 100 breast cancer patients with node positive that used fluorouracil, doxorubicin, cyclophosphamide (FAC) and docetaxel, doxorubicin and cyclophosphamide (TAC) regimen as adjuvant therapy. Patients were followed for 4 months since the end of chemotherapy. Health-related quality of life was assessed using questionnaire (QLQ-C30) from European Organization for Research and Treatment of Cancer (EORTC). Independent t-test analysis was used at the significant level of 0.05 for analyzing the results. The mean of age was 48.49 +/- 10.63 in these patients. QoL scores were 64 and 68 in TAC and FAC groups, respectively (P &lt; 0.001). After 4 months, patients in TAC and FAC groups experienced 11.45 and 7.14 units of improvement in QoL scores, respectively (P = 0.02). Although, TAC had a more negative impact on QoL during chemotherapy, it created a higher improvement than FAC during 4 months since the end of treatment. These effects on quality of life should be considered in making decision for providing and financing cancer treatments in Iran.},
  author       = {Bastani, Peivand and Ahmad Kiadaliri, Aliasghar},
  issn         = {1559-131X},
  keyword      = {Quality of life,Breast cancer,FAC,TAC,Iran},
  language     = {eng},
  number       = {S1},
  pages        = {70--74},
  publisher    = {Humana Press},
  series       = {Medical Oncology},
  title        = {Health-related quality of life after chemotherapy cycle in breast cancer in Iran},
  url          = {http://dx.doi.org/10.1007/s12032-010-9714-x},
  volume       = {28},
  year         = {2011},
}